TING-HSING CHAO2026-10-162026-10-162021-09-01Pure ID: 15087155Pure UUID: d037b680-230e-41dd-9e76-6c7bd0c3518810.1016/j.jacasi.2021.08.003https://www.scopus.com/pages/publications/85132144478https://scholars.csmu.edu.tw/handle/123456789/26826Type 2 diabetes is a major threat to human health in the 21st century. More than half a billion people may suffer from this pandemic disease in 2030, leading to a huge burden of cardiovascular complications. Recently, 2 novel antidiabetic agents, glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, reduced cardiovascular complications in a number of randomized control trials. To integrate new information and to achieve a streamlined process for better patient care, a working group was appointed by the Taiwan Society of Cardiology to formulate a stepwise consensus pathway for these therapies to reduce cardiovascular events in patients with type 2 diabetes. This consensus pathway is complementary to clinical guidelines, acting as a reference to improve patient care.18enjournal article